WASHINGTON, D.C. — The Food and Drug Administration proposed easing registration requirements for distributed drug manufacturing networks last week while expanding oversight of foreign facilities that supply ingredients entering the U.S. pharmaceutical market.
The proposed rule would allow manufacturers operating through a centralized “hub-and-spoke” structure to register multiple production units as a single establishment rather than filing separately for each location.
The change could lower registration costs and make it easier for companies to add, relocate or remove manufacturing units. Companies would be required to notify the FDA before relocating a unit, giving regulators more current information about where drugs are produced.
Distributed manufacturing networks use a central hub to oversee quality across multiple equivalent production units operating at different sites. Existing regulations generally require each unit to register independently.
“The proposed changes would make it easier for innovative manufacturers to operate efficiently, and give the FDA a clearer, more accurate picture of how and where drugs are being made,” Michael Davis, acting director of the FDA’s Center for Drug Evaluation and Research, said.
The rule would also clarify that certain foreign facilities producing drugs or active pharmaceutical ingredients for shipment to other foreign manufacturers must register with the FDA and list the products they make.
Some of those upstream facilities may not currently be registered because their products do not enter the U.S. directly, limiting the agency’s visibility into the origins of ingredients ultimately used in medicines sold to American patients.
The expanded requirements would give the FDA more information about foreign production sites and could help regulators trace ingredients and respond to potential safety or supply-chain problems.
“When an active ingredient in a medicine reaches an American patient, the FDA should be able to trace exactly where it came from,” Davis said.
The FDA expects the proposal, if finalized, to produce long-term administrative savings for manufacturers and the agency. It would also increase federal oversight of pharmaceutical supply chains as policymakers seek to strengthen domestic production and reduce reliance on less-visible foreign suppliers.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.